US › Healthcare

Aldeyra The (ALDX)

US · Healthcare · Biotechnology

$1.38+0.73%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-5.5M

EPS

$-0.16

EPS estimate

$-0.11

EPS came in at -0.16 against a street estimate of -0.11 — a miss of 45.5%.

Key statistics

Market cap

$82.6M

Forward P/E

0.0

P/B

2.20

Book value

$0.63

EPS (TTM)

$-0.38

52-week high

$5.93

52-week low

$1.07

50-day MA

$1.62

200-day MA

$2.91

Beta

1.19

Analyst view

Analysts rate Aldeyra The a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $6.60.

Shareholding

Insiders

3.60%

Institutions

61.60%

Largest institutional holders

Fund	Stake
Knoll Capital Management LP	9.08%
BlackRock Inc	6.24%
AQR Capital Management LLC	4.69%
Kingdon Capital Management LLC	4.40%
Vanguard Capital Management, LLC	3.92%
D. E. Shaw & Co LP	3.22%
683 Capital Management LLC	2.49%
Geode Capital Management, LLC	2.07%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aldeyra The — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.